Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients with ...
Combining bio-signaling innovation with sustainable practices to support wellness in electronic-heavy environments. KAOHSIUNG, KAOHSIUNG, TAIWAN, September 19, 2025 ...
While metabolomics is the large-scale comprehensive profiling of metabolites and other small molecules in the context of ...
Wearable Devices expands its AI-powered LMM technology into predictive health monitoring and cognitive state analytics, enhancing real-time health insights. Wearable Devices Ltd., a technology company ...
On Wednesday, Q32 Bio Inc. (NASDAQ:QTTB) revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA). The company plans to ...
Researchers at the University of Copenhagen have identified a signaling pathway that simultaneously increased energy expenditure and decreased food intake. In both human and primate studies, agonists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback